New combo therapy aims to keep hepatitis b in check
NCT ID NCT07588009
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a new drug called GST-HG141 (Nairecovir) combined with standard antivirals in 576 adults with chronic hepatitis B. Participants have already completed 48 weeks of treatment in an earlier study. The goal is to see if the combination is safe and helps keep the virus under control over the long term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GST-HG141 (also called Nairecovir) combined with nucleoside analog antivirals
- What this could lead to
- If successful, this could provide a new combination therapy to better control chronic hepatitis B over the long term.
- What could go wrong
- This is an extension study focused on safety and tolerability, not a cure. It builds on earlier results, but long-term benefits and risks are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data